Apollomics Inc

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.

Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder, Executive Director and President, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023 at 10:30 a.m. ET at the Lotte New York Palace in New York, NY.

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in phase 2 trials for NSCLC, GBM, and other solid tumors. They also have a second asset, APL-106, which is a specific E-Selectin antagonist being explored as a therapeutic target in certain types of cancer metastasis.

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Kaixin Auto Holdings

Reunion Neuroscience Inc

MultiMetaVerse Holdings Ltd

NanoViricides

SciSparc Ltd

Wearable Devices Ltd

Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.

The 7 Most Promising Penny Stocks to Buy in June

Apollomics focuses on therapies for hard-to-treat cancers. The company has nine therapies, with six in clinical trials.

Why Shares of Apollomics Are Up Friday

AngioDynamics

T2 Biosystems

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the company's Co-Founder and President, Sanjeev Redkar, MBA, Ph.D., will speak at the 23rd Annual R. Bryan Miller Symposium, an event exploring the interface of chemical biology and organic chemistry in honor of Professor R. Bryan Miller, at the University of California, Davis on April 14, 2023.

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

News for Apollomics Inc Stock (APLM)